Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the
worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell …

Class III β-tubulin (βIII-tubulin) is frequently overexpressed in human tumors and is
associated with resistance to microtubule-targeting agents, tumor aggressiveness, and poor …

Novel indazole and benzimidazole analogues were designed and synthesized as tubulin
inhibitors with potent antiproliferative activities. Among them, compound 12b exhibited the …

Novel coumarin-indole derivatives were designed, synthesized and evaluated as tubulin
polymerization inhibitors targeting the colchicine binding site. Among these compounds …

Introduction Rapid advances in bioengineering enable the use of complex proteins as
therapeutic agents to treat diseases. Compared with conventional small molecule drugs …

In this work, we utilized the N-benzylaryl derivative 9 as a lead compound and employed the
molecular hybridization strategy by introducing cinnamoyl fragments to successfully design …

Purpose: Sabizabulin, an oral cytoskeleton disruptor, was tested in a phase Ib/II clinical
study in men with metastatic castration-resistant prostate cancer (mCRPC). Patients and …

Extensive preclinical studies have shown that colchicine-binding site inhibitors (CBSIs) are
promising drug candidates for cancer therapy. Although numerous CBSIs were generated …

Esophageal cancer (EC) is one of the most incident and lethal tumors worldwide. Although
surgical resection is an important approach in EC treatment, late diagnosis, metastasis and …

Simple Summary The sabizabulin agent represses tumor cell growth, cell migration, and
colony formation, and induces cell death in HER2+ breast cancer models. Sabizabulin is …